PHVS affiliate files Form 144 to sell 4,667 and 4,137 shares
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice related to proposed sales of Common Stock of PHVS.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice related to proposed sales of Common Stock of PHVS. The excerpt lists 4,667 shares described as Restricted Stock with a 04/11/2025 date and 4,137 shares from a Stock Option Exercise with a 05/15/2026 date.
Insights
Form 144 records proposed affiliate resale activity, not a completed sale.
The filing excerpt lists two planned dispositions: 4,667 shares labeled Restricted Stock dated 04/11/2025, and 4,137 shares tied to a Stock Option Exercise dated 05/15/2026. Form 144 is a notice of intent to sell by an affiliate and does not itself effect a sale.
Cash‑flow treatment and whether sales were executed are not shown in the excerpt; subsequent trade reporting or broker records would confirm execution. Future filings would disclose completed transactions.
Key Figures
Key Terms
Restricted Stock financial
Stock Option Exercise financial
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the PHVS Form 144 filing show?
Who is listed as the filer on the PHVS excerpt?
What types of securities are included in this PHVS filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Keep reading
More on PHVS
- Oct 8, 2026 Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
- Oct 5, 2026 Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
- Sep 8, 2026 Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks